Inhibiting system xC− and glutathione biosynthesis – a potential Achilles' heel in mutant-p53 cancers
Effective therapeutic strategies to target mutant tumor protein p53 (TP53, best known as p53) cancers remain an unmet medical need. We found that mutant p53 impairs the function of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2, commonly known as NRF2), suppresses solute carrier family 7 member...
Main Authors: | Nicholas J. Clemons, David S. Liu, Cuong P. Duong, Wayne A. Phillips |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-09-01
|
Series: | Molecular & Cellular Oncology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/23723556.2017.1344757 |
Similar Items
-
Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies
by: Jolanda Magri, et al.
Published: (2021-01-01) -
Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells
by: Benoit Tessoulin, et al.
Published: (2019-03-01) -
Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models
by: Giuseppina Barutello, et al.
Published: (2022-11-01) -
A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
by: Sophia Ceder, et al.
Published: (2020-12-01) -
Antitumor Effects of PRIMA-1 and PRIMA-1<sup>Met</sup> (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
by: Paola Menichini, et al.
Published: (2021-01-01)